NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT02794428 2024-10-16
Chemoprevention of Gastric Carcinogenesis
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT01059071 2024-08-06
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Phase 1 Completed
NCT02395666 2024-08-06
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
Phase 2 Completed
NCT01483144 2021-06-08
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00983580 2019-09-04
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006101 2018-05-14
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
University of California, Irvine
Phase 2 Completed
NCT00601640 2017-03-23
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
University of Arizona
Phase 2 Completed
NCT00118365 2015-01-22
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
National Cancer Institute (NCI)
Phase 3 Completed